Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1131-1134

  Di Leo, E ^a   Aloia, A M ^a   Nettis, E ^a   Cardinale, F ^a   Foti, C ^a   Distaso, M ^a   Ferrannini, A ^a   Vacca, A ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

COX 2 inhibitors; Etoricoxib; Long tolerability

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ARYLACETIC ACID DERIVATIVE; ARYLPROPIONIC ACID DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ETORICOXIB; FENETIDINIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PYRAZOLONE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SULPHONALIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHINITIS; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 76349093134     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200431     Document Type: Article

References (8)

1. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to non-steroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977; 60:276-84.
2. Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T. Intolerance to non-steroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996; 98:678-85.
3. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832-6.
4. Asero R. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clin Exp Dermatol 2007; 32:661-3.
5. Nettis E, Di Paola R, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 88:331-4.
6. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005; 94:29-33.
7. Colanardi MC, Nettis E, Tfaetta P, Daprile C, Fitto C, Aloia AM, Di Leo E, Ferrannini A, Vacca A. Safety of parecoxib in patients with non-steroidal anti-inflammatory drug-induced urticaria or angioedema. Ann Allergy Asthma Immunol 2008; 100:82-5.
8. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97:105-9.